Piramal Pharma Limited · NSE:PPLPHARMA
Piramal Pharma — Q3 FY2025 Earnings Presentation
25 slides from Piramal Pharma's earnings presentation, Jan 28, 2025
Slide 1: Exchange cover letter for results and investor presentation
28th January, 2025 BSE Limited National Stock Exchange of India Limited P.J. Towers, Dalal Street, Fort, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (East), Mumbai – 400 051 BSE scrip code: 543635 NSE symbol: PPLPHARMA Sub: Press Release and Investor Presentation – Unaudited Financi
Slide 2: Piramal Pharma Limited Announces Results for Q3 and 9M FY25
PRESS RELEASE Piramal Pharma Limited Announces Results for Q3 and 9M FY25 Mumbai, India | January 28, 2025: Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceuticals and wellness company, today announced its standalone and consolidated results for the Third Quarter (Q3)
Slide 3: Key Business Highlights for Q3 and 9M FY25
Key Business Highlights for Q3 and 9M FY25 Contract Development and Manufacturing Organization (CDMO): - CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business - Timely capacity expansions and target
Slide 4: Consolidated Profit and Loss Statement
Consolidated Profit and Loss Statement (in ₹ Cr. or as stated) Quarterly Nine Months Particulars Q3FY25 Q3FY24 YoY Change 9MFY25 9MFY24 YoY Change Revenue from Operations 2,204 1,959 13% 6,397 5,619 14% Other Income 12 62 (80)% 93 149 (38)% Total Income 2,216 2,020 10% 6,490 5,768 13% Material Cost
Slide 5: Q3FY25/9MFY25 Earnings Conference Call
Q3FY25/9MFY25 Earnings Conference Call Piramal Pharma Limited will be hosting a conference call for investors / analysts on 29th January 2025 from 5:30 PM to 6:15 PM (IST) to discuss its Q3 and 9M FY25 Results. The dial-in details for the call are as under: Event Location & Time Telephone Number +91
Slide 6: Q3 & 9M FY2025 Results
Q3 & 9M FY2025 Results January 2025
Slide 7: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Piramal Pharma Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation, directly or indirectly, in any manner,
Slide 8: Key Performance Highlights of Q3FY25 / 9MFY25
Key Performance Highlights of Q3FY25 / 9MFY25 Revenue from Operation 9MFY25 Revenue Break‐up (In ₹ Crore) 13% 14% 13% 2,204 6,397 1,959 5,619 30% 57% Q3FY24 Q3FY25 9MFY24 9MFY25 EBITDA and EBITDA Margins (In ₹ Crore) 850 100% 1200 100% EBITDA 17% 16% 15% 15% 90% 90% 750 1100 Margin 650 80% 80% 1000
Slide 9: Key Performance Highlights of Q3FY25 / 9MFY25 by business
Key Performance Highlights of Q3FY25 / 9MFY25 Key Highlights Revenue (In ₹ Cr) and Growth 13% 18% • Continued momentum in revenue from on‐patent commercial manufacturing 3,659 CDMO • YoY improvement in EBITDA margin driven by operating leverage and cost optimization 3,101 1,134 1,278 • Converted coa
Slide 10: Business Wise Performance
Business Wise Performance
Slide 11: CDMO Business
CDMO Business Performance Highlights Revenue Growth (In ₹ Crore) Robust high‐teen revenue growth in 9MFY25 driven by: • Continued momentum in on‐patent commercial manufacturing 13% 18% • Healthy demand in generic API business 3,659 • Timely capacity expansions and targeted BD1 efforts driving incr
Slide 12: Maintaining our Best-in-Class Quality Track Record
Maintaining our Best‐in‐Class Quality Track Record 360+ Regulatory Inspections with no OAI ~130 Audits Annually by Customers US FDA Inspections Total Regulatory Inspections 44 36 36 197 35 167 163 172 29 29 157 148 26 27 140 141 142 25 24 116 115 17 42 99 14 32 32 13 26 35 71 10 21 20 24 29 60 10 23
Slide 13: A Significant Step Towards Sustainable Operations
A Significant Step Towards Sustainable Operations Converted the coal‐fired steam boiler at our Digwal facility to operate on biomass briquettes, a carbon‐neutral fuel source • Will eliminate ~24,000 tCO2e GHG emissions annually, accounting for ~17% of total emissions • The shift to biomass briquette
Slide 14: Complex Hospital Generics Business
Complex Hospital Generics Business Performance Highlights Revenue Growth (In ₹ Crore) Inhalation Anesthesia • IA sales in the US tracking healthy volume growth driven by order wins for 14% 8% Sevoflurane and Isoflurane • Maintain our #1 Rank in Sevoflurane in the US with over 40%* market share • R
Slide 15: India Consumer Healthcare Business
India Consumer Healthcare Business Performance Highlights Revenue Growth (In ₹ Crore) New Product launches ‐ 16 new products and 23 new SKUs launched in 9MFY25 10% 10% 819 747 Power Brands grew 19% YoY during 9MFY25, contributing 48% to total ICH sales • Excluding i‐range (impacted by regulatory
Slide 16: Investing for Profitable Growth
Investing for Profitable Growth Continuous Media and Trade Spends… …Fueling Growth of Power Brands… (In ₹ Crore) (In ₹ Crore) % of ICH 16% 15% 15% 448 sales 396 13% 370 45000% 16% 200 12% 14% 40000% 268 35000% 131 131 12% 116 150 30000% 98 194 10% 84 25000% 8% 100 20000% 6% 15000% 4% 50 10000% 2% 50
Slide 17: Onboarded Sai Ramana Ponugoti – CEO, ICH Business
Onboarded Sai Ramana Ponugoti – CEO, ICH Business With over 20 years of leadership experience at Procter & Gamble (P&G), Mr. Sai Ramana Ponugoti has held senior roles across India, Asia, the Middle East, and Africa. As the Chief Sales Officer for P&G India, he has led transformative disruptions, dri
Slide 18: Financials
Financials
Slide 19: Consolidated Financials Highlights
Consolidated Financials Highlights (in ₹ Cr. or as stated) Particulars Q3FY25 Q3FY24 YoY Change 9MFY25 9MFY24 YoY Change Revenue from Operations* 2,204 1,959 13% 6,397 5,619 14% CDMO 1,278 1,134 13% 3,659 3,101 18% CHG 654 576 14% 1,928 1,782 8% ICH 278 252 10% 819 747 10% EBITDA 350 330 6% 977 815
Slide 20: Strategic Goals
Strategic Goals
Slide 21: Financial Aspirations for FY2030
Financial Aspirations for FY2030 3x 2x 1x Over 3x Growth in More than Double the Reduce Leverage EBITDA Revenues on the Balance Sheet ~25% US$2+ Bn ~1x EBITDA Margins Revenue NetdebttoEBITDA Exponential Growth Enhance ROCE in PAT Early Teens PAT Margins High Teens ROCE Note:‐ The aspirations mention
Slide 22: US$2+ Bn Company with 25% EBITDA Margin by FY2030
US$2+ Bn Company with 25% EDITDA Margin by FY2030 Strategic Goals for FY2030 US$1.2 Bn revenues with ~25% US$600 Mn revenues with 25%+ US$200 Mn revenues with double‐digit EBITDA margin EBITDA margin EBITDA margin CDMO CHG ICH Emerge as a fast‐growing, innovation‐ Become a leading critical carecompa
Slide 23: Key Investment Highlights
Key Investment Highlights US$2+ Bn Global Pharma, Health & Wellness Company by FY2030 1 Strong promoter group with over 35 years of demonstrated ability to build scalable and differentiated businesses 2 Presence in large multi‐billion dollar size attractive industry segments with promising tailwinds
Slide 24: Dial-in details for Q3 and 9M FY25 Earnings Conference Call
Dial‐in details for Q3 and 9M FY25 Earnings Conference Call Event Location & Time Telephone Number +91 22 6280 1461 / +91 22 7115 8320 (Primary Number) India – 05:30 PM IST 1 800 120 1221 (Toll free number) Conference USA – 07:00 AM Toll free number Call on 29th (Eastern Time – New York) 18667462133
Slide 25: For Investor Queries
For Investor Queries: Gagan Borana Madhusudan Dalmia Investor Relations and Enterprise Risk Management Investor Relations Email: gagan.borana@piramal.com Email: madhusudan.dalmia@piramal.com